Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
Cátia Dias,
Filipa Duarte-Ribeiro,
Sara Pipa,
Ana Rita Barbosa,
Margarida Mota,
Fernando Rosas Vieira
Affiliations
Cátia Dias
Corresponding author at: Rua Dr.º Francisco Sá Carneiro, 1228 1º esquerdo, São Cosme, 4420-132 Gondomar, Porto, Portugal.; Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
Filipa Duarte-Ribeiro
Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
Sara Pipa
Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
Ana Rita Barbosa
Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
Margarida Mota
Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
Fernando Rosas Vieira
Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia / Espinho, Portugal
The newer oral treatments for chronic hepatitis C virus infection are one of the greatest revolutions in modern medicine. These drugs promise to eradicate the infection, showing high cure rates even in difficult to treat populations with very few side effects. Nevertheless, some cases of recurrence and de novo hepatocellular carcinoma after treatment with these drugs have been reported. We describe two cases of patients treated with direct-acting antiviral agents that developed hepatocarcinoma during follow-up post-treatment. Keywords: Hepatocellular carcinoma, HCV infection, Direct-acting antiviral therapy
